Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 913 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04297605RecruitingPhase 1
Pembrolizumab plus chemotherapy for advanced lung cancer
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
Rochester, New YorkAges 18 years+ - NCT06848699RecruitingPhase 1/Phase 2
Testing HLX43 plus Serplulimab for advanced solid tumors
This trial tests a new combination of two cancer drugs (HLX43 and Serplulimab) for people with advanced solid tumors, especially those with a specific type of lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can shrink tumors or slow their growth.
Hunan, ChangshaAges 18–75 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT06532279RecruitingPhase 2
Testing BMX-001 with chemoradiation for head and neck cancer
This trial tests whether adding BMX-001 (a drug that may protect healthy tissues) to standard chemoradiation can reduce side effects and improve outcomes for people with head and neck cancer. It's a randomized study, so you would have a 50/50 chance of getting BMX-001 or a placebo.
Gilbert, ArizonaAges 18 years+ - NCT07269782RecruitingPhase 2
Pre-surgery treatment for stage II-III lung cancer
This study tests two investigational drugs (HLX43 and serplulimab) given before surgery to people with stage II to III non-small cell lung cancer (NSCLC). The goal is to see if these drugs can shrink the tumor and make it easier to remove completely during surgery.
ShanghaiAges 18–75 - NCT06364917RecruitingPhase 2
Comparing two immunotherapy options for PD-L1 negative lung cancer
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Birmingham, AlabamaAges 18–89 - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06997068RecruitingPhase 2
Drug combination for returning head and neck cancer
This trial tests a combination of three drugs—methotrexate, erlotinib, and celecoxib—for people whose head and neck cancer has come back or spread. It is designed for patients in the rural Midwest who have already had or chosen not to have standard first treatment.
Rochester, MinnesotaAges 18 years+ - NCT06623396RecruitingPhase 1
Mesothelin-targeted CAR T cells for esophagogastric cancer or mesothelioma
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
Basking Ridge, New JerseyAges 18 years+ - NCT02734537RecruitingPhase 2
Radiation with or without cisplatin after head and neck surgery
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
Birmingham, AlabamaAges 18 years+ - NCT04199741RecruitingPhase 1/Phase 2
PET/CT scan test for small cell lung cancer marker DLL3
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
New York, New YorkAges 18 years+ - NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT07772895RecruitingPhase 1
Glowing dye to help surgeons see lung cancer during surgery
This trial tests a dye that makes lung cancer cells glow during surgery, helping surgeons remove more of the tumor. It's for people who are already scheduled for lung cancer surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07316010RecruitingPhase 2
Liso-cel for lymphoma with minimal residual disease after first treatment
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT07508995RecruitingPhase 2
New pill combo for untreated chronic lymphocytic leukemia
This trial tests a new pill combination for chronic lymphocytic leukemia (CLL) that has not been treated before. The drugs are designed to attack CLL cells in two different ways to try to improve outcomes.
Houston, TexasAges 18 years+ - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT06045247RecruitingPhase 2
Epcoritamab with gentler chemo for older adults with lymphoma
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
Houston, TexasAges 18 years+
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 913 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.